UBS analyst David Dai lowered the firm’s price target on Syndax (SNDX) to $35 from $37 and keeps a Buy rating on the shares. UBS expects Syndax to report in-line Q2 results with $25M in Revuforj sales and $2.7M in Niktimvo revenue, but thinks Niktimvo sales could surprise to the upside even the strong Q1 launch, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- 3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential
- Syndax Pharmaceuticals’ Axatilimab Study: A Potential Breakthrough for IPF Treatment
- Syndax initiated with a Buy at Goldman Sachs
- Promising Growth Potential for Syndax Pharmaceuticals Driven by Revuforj and Strategic Partnerships
- William Meury Resigns from Syndax Pharmaceuticals Board